244 related articles for article (PubMed ID: 28926265)
1. Tobacco Mosaic Virus-Delivered Cisplatin Restores Efficacy in Platinum-Resistant Ovarian Cancer Cells.
Franke CE; Czapar AE; Patel RB; Steinmetz NF
Mol Pharm; 2018 Aug; 15(8):2922-2931. PubMed ID: 28926265
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-Loaded Tobacco Mosaic Virus for Ovarian Cancer Treatment.
Zhao Z; Simms A; Steinmetz NF
Biomacromolecules; 2022 Oct; 23(10):4379-4387. PubMed ID: 36053908
[TBL] [Abstract][Full Text] [Related]
3. Tobacco Mosaic Virus with Peroxidase-Like Activity for Cancer Cell Detection through Colorimetric Assay.
Guo J; Zhao X; Hu J; Lin Y; Wang Q
Mol Pharm; 2018 Aug; 15(8):2946-2953. PubMed ID: 29300485
[TBL] [Abstract][Full Text] [Related]
4. Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy.
Czapar AE; Zheng YR; Riddell IA; Shukla S; Awuah SG; Lippard SJ; Steinmetz NF
ACS Nano; 2016 Apr; 10(4):4119-26. PubMed ID: 26982250
[TBL] [Abstract][Full Text] [Related]
5. Tobacco mosaic virus delivery of mitoxantrone for cancer therapy.
Lin RD; Steinmetz NF
Nanoscale; 2018 Aug; 10(34):16307-16313. PubMed ID: 30129956
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.
Zhang M; Hagan CT; Min Y; Foley H; Tian X; Yang F; Mi Y; Au KM; Medik Y; Roche K; Wagner K; Rodgers Z; Wang AZ
Biomaterials; 2018 Jul; 169():1-10. PubMed ID: 29631163
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance.
Gao Y; Jiang M; Ma Y; Wu S; Li W; Yang X; Li Y; Jing X; Jiang H
Anticancer Drugs; 2016 Feb; 27(2):77-83. PubMed ID: 26473527
[TBL] [Abstract][Full Text] [Related]
8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
9. Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles.
Kernan DL; Wen AM; Pitek AS; Steinmetz NF
Exp Biol Med (Maywood); 2017 Aug; 242(14):1405-1411. PubMed ID: 28675044
[TBL] [Abstract][Full Text] [Related]
10. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Krieger ML; Eckstein N; Schneider V; Koch M; Royer HD; Jaehde U; Bendas G
Int J Pharm; 2010 Apr; 389(1-2):10-7. PubMed ID: 20060458
[TBL] [Abstract][Full Text] [Related]
11. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
13. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
15. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-targeting zeolitic imidazole frameworks to overcome platinum-resistant ovarian cancer.
Xing Y; Jiang Z; Akakuru OU; He Y; Li A; Li J; Wu A
Colloids Surf B Biointerfaces; 2020 May; 189():110837. PubMed ID: 32058250
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study.
Bagherpour Doun SK; Alavi SE; Koohi Moftakhari Esfahani M; Ebrahimi Shahmabadi H; Alavi F; Hamzei S
Tumour Biol; 2014 Aug; 35(8):7491-7. PubMed ID: 24789433
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
20. Axl molecular targeting counteracts aggressiveness but not platinum-resistance of ovarian carcinoma cells.
Corno C; Gatti L; Arrighetti N; Carenini N; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2017 Jul; 136():40-50. PubMed ID: 28404378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
